Introduction
Goodpasture's disease, also called anti-glomerular basement membrane (GBM) disease, is a rare but severe autoimmune disease characterized by the presence of anti-GBM autoantibodies and the rapid progression of glomerulonephritis, frequently accompanied by pulmonary haemorrhage. 1, 2 The major target antigen is non-
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collagenous domain 1 (NC1) of the a3 chain of collagen IV, which intertwines, forming an a345 triple helical network in the basement membrane of glomerular and alveolar capillaries. The a3NC1 domain harbours two well-defined B-cell epitopes: E A and E B. 3, 4 The linear peptide containing E B , designated as P14 (a3 127-148 ) (TDIPPCPHGWISLWKGFSFIMF), was demonstrated as a T-cell epitope 5 and was recognized by antibodies from patients with anti-GBM disease. 6 This disease is an ideal model for studies on mechanisms of autoimmune disease aetiology, in which genetic predispositions act as 'first hits' that combine with 'second hits' such as infection and chemical substances. 7 Studies on four well-controlled Caucasian groups reported that most (approximately 80%) patients with anti-GBM disease carry the human leucocyte antigen (HLA)-DRB1*1501 allele. 8 This finding was confirmed in Asian populations. [9] [10] [11] The critical T-cell epitope presented by this molecule is a3 [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] , and a3 136-146 -specific CD4 + T-cell clones generated from DRB1*1501 transgenic mice could transfer the disease to naive DRB1*1501 transgenic mice. 12 However, other HLA-DRB1 alleles also have hierarchical influence on disease susceptibility. 8, 13 Furthermore, HLA-DRB1 alleles present different linkage disequilibria with other HLA class II alleles, i.e. the DQA1 and DQB1 alleles.
14 These linkages might interfere with the results interpretation for HLA-DRB1 and conceal significant findings for other alleles.
HLA II molecules possess distinctive peptide-binding characteristics that selectively bind and present antigenderived peptides to CD4 + T cells and influence autoimmune responses. 15, 16 Structural comparisons of HLA II molecules associated with anti-GBM disease are helpful in interpreting allele analysis findings by distinguishing the involvement of these alleles from linkage disequilibrium. 8 Defining the pathogenic interactions of HLA molecules with autoantigenic peptides is also important for developing more specific immunotherapies, 17 such as synthetic peptides that block these interactions, induce tolerance, or act as T-cell receptor antagonists. However, few studies have analysed the susceptible amino acid residues on HLA molecules on Goodpasture's disease.
This study enrolled the largest cohort of 140 patients with Goodpasture's disease and 599 geographically matched controls. We typed the HLA-DRB1, -DQA1, -DQB1 and -DPB1 allele genotypes at four-digit resolution and investigated the disease associations with HLA class II alleles, haplotypes and risk amino acid residues on the HLA-DRb1, -DQa1, -DQb1 and -DPb1 chains of HLA molecules. We made a model of the P14 peptide bound to the DR2b molecule to infer elements critical for binding, which may provide information for the future design of immunotherapies.
Materials and methods

Participants
The patient group comprised 140 Chinese patients with anti-GBM disease who presented with rapidly progressive glomerulonephritis with or without pulmonary haemorrhage. Diagnosis was established in all cases based on the detection of serum anti-GBM autoantibodies through ELISA using bovine a3(IV)NC1 (Euroimmun, L€ ubeck, Germany) and recombinant human a3(IV)NC1 as solidphase ligands 18 and detection of linear immunoglobulin G deposits along the GBM under direct immunofluorescence in all renal biopsies. The control group comprised 599 healthy Chinese individuals voluntarily recruited as blood donors and geographically matched with the patients. This research was performed in compliance with the Declaration of Helsinki and approved by the Peking University First Hospital ethics committee. Written informed consent was obtained from all participants. All of the authors vouch for the accuracy and completeness of the data.
HLA allele genotyping
Peripheral blood samples (10 ml) were collected from patients and controls using anticoagulant EDTA. Genomic DNA was obtained from peripheral blood leucocytes using the Puregene Blood Core Kit C (Cat. No. 158389, Qiagen Science, Hilden, Germany).
HLA-DRB1, -DQB1 and -DPB1 sequencing was performed on an Applied Biosystems 3130xl platform using SeCoreâ Sequencing Kits (Invitrogen, Carllsbad, CA). HLA allele typing reports were issued using UTYPE SBT HLA software. HLA-DRB1, -DQB1 and -DPB1 typing was performed using bidirectional sequencing of exon 2, exons 2 and 3, and exons 2, 3 and 4, respectively; HLA-DQA1 alleles were typed using electrophoresis.
Extraction of amino acid sequences of HLA-DRb1, -DQa1, -DQb1, and -DPb1 chains Based on four-digit resolution HLA alleles, the amino acid sequences of the HLA-DRb1, -DQa1, -DQb1 and -DPb1 chains were extracted from the IMGT/HLA public database (http://www.ebi.ac.uk/ipd/imgt/hla/).
Association analysis
All genotyping data sets were subjected to the same rigorous quality assessments both before and after cases and controls were compared. Individuals for whom consistent genotypes could not be obtained for each locus were removed from the study. Missing genotypes were reconstructed; Hardy-Weinberg equilibrium was assessed at each locus. HLA alleles were excluded from the analysis if they were out of Hardy-Weinberg equilibrium (P < 0Á001) or had minor allele frequency < 0Á001. Unconditional and stepwise conditional analyses for HLA class II alleles and the amino acid positions of HLA-DRB1, -DQA1, -DQB1 and -DPB1 were performed through logistic regression using PLINK version 1.9 (http://www.cog-genomics.org/ plink/1.9/). 19 HLA class II allele haplotypes were constructed using the EM algorithm with R Project 3.1.1 (haplo.stats package) (http://www.r-project.org). 20 Differences were considered significant when P < 0Á05 per distinct allele or per distinct amino acid position.
Markers were obtained and encoded to determine association analysis. Bi-allelic markers with two HLA alleles or two-residue amino acid positions were encoded as alleles 1 and 2. Multi-allelic (three or more alleles) markers were encoded as the presence and absence of each allele of multi-residue amino acid positions. A log likelihood ratio test, estimating the log likelihood differences reflecting the effects at a single amino acid position, was used to evaluate the anti-GBM disease association at an amino acid position. Associations with anti-GBM disease risk were evaluated using logistic regression analysis. 21 
Modeller
The amino acid sequence of type IV collagen a3 chain was extracted from Protein (http://www.ncbi.nlm.nih.gov/ protein). We used SYFPEITHI online database (http://www. syfpeithi.de/) to predict the T-cell epitopes of a3(IV)NC1. All predicted MHC class II ligands are 15-mers, consisting of three N-terminal flanking residues, the nonamer core sequence located within the binding groove, and three C-terminal flanking residues. Hence, anchor residue P1 appears in position 4 of the peptides predicted with SYFPEITHI. 22 The protein crystal structure of 1YMM (http:// www.rcsb.org/pdb/home/home.do) was used as a template to construct DR2b-peptide-TCR structural models using the MODELLER program (version 9V8, http://salilab.org/ modeller/). [23] [24] [25] [26] [27] We moved the peptides (PCPHGWISLWKGFSFIMF) 'step by step' and sought the optimum structure. MODEL-LER refine was set very slowly and optimization was repeated six times. Ending model was set as 800. The conformations of 800 compounds were exported from every 'move' and manually evaluated according to the following criteria. We measured the distance between amino acid residues of a3(IV)NC1 peptides and corresponding peptide binding pockets at the first step (DR2b: distancepocket 1 ≤ 4 A, distance-pocket 4 ≤ 4 A, distance-pocket 7 ≤ 4 A). We chose the position with the shortest distance as the optimum position. Then we measured distance between the guanidino nitrogen atom of arginine on position 13 encoded by DRB1*1501 and the carbonyl oxygen atom of the main chain of the amino acid residue located in pocket 4. We set the distance below 3Á5 A and chose the conformations with shortest distance as the optimum structure.
Results
Population characters
The patient group comprised 140 Chinese Han patients with biopsy-proven anti-GBM disease. The control group comprised 599 healthy, voluntarily recruited Chinese Han blood donors who had been racially matched with the patients.
Association of HLA alleles with Goodpasture's disease
A total of 141 distinct HLA alleles were identified in the patients and controls: 46 DRB1, 19 DQA1, 22 DQB1 and 54 DPB1. The threshold for statistical significance was set as P < 0Á05/141 (3Á6 9 10 À4 ) in classic HLA allele association analysis. Unconditional analysis revealed a positive association between the disease and DRB1*1501 (OR = 4Á6, P = 5Á7 9 10 À28 ), DQB1*0602 (OR = 3Á3, P = 2Á0 9 10 À17 ) and DQA1*0502 (OR = 30Á7, P = 7Á0 9 10 À7 ) alleles. There were negative associations between the disease and DQB1*0303 (OR = 0Á3, P = 8Á6 9 10 À6 ) and DRB1*0901
(OR = 0Á4, P = 1Á6 9 10 À4 ) alleles (Table 1 , Fig. 1a ).
After adjusting for DRB1*1501 under stepwise conditional analysis, no other HLA allele showed an association with the disease, reflecting the strong influence of DRB1*1501 on anti-GBM disease (Fig. 1b) . When adjusting for DQB1*0602, the close association between DRB1*1501 and anti-GBM disease (P = 1Á7 9 10 À9 ) remained (Fig. 1c) .
Linkage disequilibrium among HLA alleles
Linkage disequilibrium was analysed among the three susceptibility alleles (DRB1*1501, DQB1*0602, DQA1*0502) and two protective alleles (DRB1*0901, DQB1*0303) described above. Risk allele, DRB1*1501 was in overt linkage disequilibrium with DQB1*0602 (D' = 0Á56, r 2 = 0Á31). The protective allele DRB1*0901 was in overt linkage disequilibrium with DQB1*0303 (D' = 0Á56, r 2 = 0Á31). However, the susceptibility allele DQA1*0502 was not in linkage disequilibrium with the other two susceptibility alleles or the protective alleles (Table 2) .
HLA haplotypes associated with Goodpasture's disease
The association of HLA haplotypes with Goodpasture's disease was analysed using the EM algorithm via R Project.3.1. our cases and healthy controls, and we set P = 1Á0 9 10
À4
as the threshold for statistical significance. The analysis revealed positive associations between HLA haplotypes and anti-GBM disease. When two loci were analysed together, DRB1*1501-DQB1*0602 haplotype was positively associated with the disease (score = 8Á8, P = 9Á7 9 10 À19 ). When three loci were analysed in combination, DRB1*1501-DQA1*0102-DQB1*0602 was positively associated with the disease (score = 4Á6, P = 1Á0 9 10 À6 ). When four loci were analysed, DRB1*1501-DQA1*0102-DQB1*0602-DPB1*0201 was positively associated with the disease (score = 3Á5, P = 4Á2 9 10 À4 ) ( Table 3) .
HLA haplotype analysis also revealed negative associations between haplotypes and anti-GBM disease. DRB1*0901-DQB1*0303 (haplotype score = À4Á3, P = 1Á6 9 10
À5
), DRB1*0901-DQA1*0302-DQB1*0303
(score = À4Á5, P = 7Á3 9 10
À6
), and DRB1*0901-DQA1*0302-DQB1*0303-DPB1*0501 (score = À3Á5, P = 4Á2 9 10 À4 ) all showed negative associations with the disease (Table 3) .
Association of HLA amino acid residues with Goodpasture's disease
The amino acid residues of the HLA-DRb1, -DQa1, -DQb1 and -DPb1 chains were analysed for associations with anti-GBM disease. We successfully imputed 152 polymorphic amino acid positions among DRb1, DQa1, DQb1 and DPb1 based on the corresponding HLA alleles at four-digit resolution. Hence we set P < 0Á05/152 (3Á3 9 10 À4 ) as the threshold for statistical significance.
Unconditional analysis revealed that the most significant association was mapped to the amino acid position 13 (P = 1Á3 9 10 À24 ) on HLA-DRb1 chain (Table 4 , Fig. 2a ), which locates in the fourth peptide-binding pocket. Arginine (ARG) at position 13 (ARG13) showed a risk effect for the disease (OR = 4Á0, P = 1Á0 9 10 À17 ).
Serine (SER) 13 and phenylalanine (PHE) 13 were protective against the disease (SER13: OR = 0Á4, P = 4Á9 9 10 À6 ; PHE13: OR = 0Á4, P = 1Á6 9 10 À4 ) ( Table 4 , Fig. 3) . A similar level of significance was observed at position 11 (P = 2Á8 9 10 À24 ) on DRb1 (Table 4 , Fig. 2a ), which locates in the sixth peptide-binding pocket. Proline (PRO) 11 increased anti-GBM disease risk (OR = 4Á0, P = 2Á0 9 10 À17 ), while SER11 and aspartic acid (ASP)
11 were negatively associated with the disease (SER11: OR = 0Á4, P = 2Á5 9 10
À9
; ASP11: OR = 0Á4, P = 3Á0 9 10 À4 ) ( Table 4 , Fig. 3 ). DRB1*1501 encodes both PRO11 and ARG13. DRB1*0901 encodes both ASP11 and PHE13. There was extremely close correlation (LOD = 98) between positions 11 and 13 on DRb1. Conditional analysis adjusting for position 11 or 13 completely eliminated the association of the other position with disease (Fig. 2b,c) . No amino acid position was associated with disease risk after conditioning on both positions 13 and 11 (Fig. 2d) .
Modelling of P14 presented by susceptible DR2b molecule
We used the SYFPEITHI online database 22 to predict T-cell epitopes of a3(IV)NC1 presented by DRB1*1501. Peptide (HGWISLWKGFSFIMF), a3 134-148 , was found with the highest score of 30. It is inside the T-cell epitope a3 129-148 , which is revealed previously from anti-GBM patients. 5 We constructed the structure of DR2b-peptide (PCPHGWISLWKGFSFIMF) using the MODELLER program. [23] [24] [25] [26] The optimum structure is shown in Fig. 4(a) . The amino acid residues, isoleucine 137 , tryptophan 140 , glycine 142 , phenylalanine 143 and phenylalanine 145 , were presented in peptide-binding pockets 1, 4, 6, 7, 9 of DR2b separately ( Table 5 , Fig. 4a ). The distance between guanidino nitrogen atom of ARG13, encoded by DRB1*1501, and the carbonyl oxygen atom of tryptophan 140 backbone in pocket 4 is 3Á3 A, which facilitates the formation of hydrogen bond. The 71st amino acid residue of DR2b bchain, ALA71, is a small residue and has no interaction with peptide. However, alanine makes pocket 4 larger than other MHC DR molecules, hence the indole ring of tryptophan 140 could stretch into this pocket. Furthermore, tryptophan 140 on the peptide and two residues in pocket 4 of DRB1*1501, PHE26 and TYR78, form strong hydrophobic interactions with each other (Table 5 , Fig. 4b ).
Discussion
In this study, we confirmed DRB1*1501 allele and its bearing haplotype (DRB1*1501-DQA1*0102-DQB1*0602-DPB1*0201) were associated with susceptibility to Goodpasture's disease in a large cohort of Chinese patients. Furthermore, we conducted an initial case-control study on HLA analysis at amino acid level. The results demonstrated the effect of coding variants from HLA class II genes and revealed that ARG13 on peptide-binding pocket 4 on DRb1, encoded by DRB1*1501, interacts with tryptophan 140 on a3 134-148 and facilitates the T-cell epitope presentation of Goodpasture's disease. These findings may clarify the mechanism of DRB1*1501 susceptibility and provide useful information for the future design of immunotherapies through amino acid mutations.
The peptide a3 129-148 (IPPCPHGWISLWKGFSFIMF) was recognized by T cells from patients with Goodpasture's disease. 5 This peptide was predicted again in the current study as the most likely T-cell epitope presented by DRB1*1501. High affinity of P14 containing core sequence binding to HLA-DR15 had also been demonstrated. 28, 29 ARG13 in pocket 4 encoded by DRB1*1501 interacts with tryptophan 140 on P14 and forms hydrogen bond. ALA71 creates larger space of pocket 4 and facilitates the indole ring of tryptophan 140 stretching into the pocket. Furthermore, PHE26 and TYR78 also form strong hydrophobic interactions with tryptophan 140 on P14. These risk residues encoded by DRB1*1501 and the molecule structure of MHC-DR2b help us to understand the mechanism of antigen presentation process for P14 on Goodpasture's disease.
Critical amino acid residues on a3 127-148 presented by DRB1*1501 was deduced by molecule modelling. We found isoleucine (I) 137 , tryptophan (W) 140 , glycine (G) 142 , 
PHE, phenylalanine; GLY, glycine; HIS, histidine; ARG, arginine; SER, serine; TYR, tyrosine; ASP, aspartic acid; LEU, leucine; PRO, proline; VAL, valine. P < 3Á3*10 À4 are shown in bold.
ª 2017 John Wiley & Sons Ltd, Immunology, 151, 395-404 12 characterized a nephritogenic T-cell epitope on a3(IV)NC1 using HLA-DRB1*1501 transgenic mice and found that by substitution of V 137 , W 140 , G 142 or F 143 resulted in the loss of T-cell epitope activity. Goodpasture antigen is a highly conservative protein during evolution. V 137 corresponds to I 137 in human a3(IV)NC1. Hence four of the critical residues had been proven for T-cell epitope through animal experiments. The last three residues, glycine 142 , phenylalanine 143 and phenylalanine 145 , were exactly the critical motif for B-cell recognition of P14, which was revealed in our previous study from patients with Goodpasture's disease. 6 All these studies defined the critical residues on region a3 127-148 and obtained highly consistent results. We further deduced the presentation pattern for these critical residues by DRB1*1501. Functional assays are required to confirm the importance of the proposed critical amino acids on T-cell activation. These findings may be important for further investigations on the disease aetiology and the potential immunotherapies using these residues.
We also revealed a high-risk association between DQA1*0502 and Goodpasture's disease and few linkage with DRB1*1501. Although DQA1*0502 did not show significant association after conditioning on DRB1*1501, we could not exclude DQA1*0502 as a susceptibility allele for the following reasons. First, DQA1*0502 is a rare allele in healthy individuals. We used the Allele Frequency Net Database (http://www.allelefrequencies.ne t/) and evaluated 10 independent European studies with a total sample size of 1307 Caucasians, and found that DQA1*0502 allele frequency was 0Á038%. No finding on DQA1*0502 has been reported among Chinese populations. Therefore, the 5% allele frequency obtained from patients with anti-GBM disease in this study is a striking high frequency. Second, DQA1*0502 represents a single C-to-G transversion in codon 59 (exon 2), and the results showing an amino acid residue change from proline to arginine, previously demonstrated to be conserved in human DQa1 polypeptides, 30 would alter the HLA-DQ molecule structure and function and influence antigen-presenting process. Hence, we proposed that DQA1*0502 might be a more specific risk allele for anti-GBM disease.
Our results revealed that DQB1*0602 is a risk allele for Goodpasture's disease; however, the significant association of this allele may reflect strong linkage with DRB1* 1501. Recent studies on DRB1*1501 and DQB1*0602 transgenic mice with 'humanized' multiple sclerosis offered a rationale for the pathogenic involvement of DQB1* 0602 in susceptibility to multiple sclerosis. 31, 32 However, the susceptible role for DQB1*0602 to Goodpasture's disease is insufficient because of the lack of evidence.
In our study, DRB1*0901 was negatively associated with Goodpasture's disease. The haplotypes bearing DRB1*0901 were also protective against the disease. PHE13 and ASP11 are both encoded by DRB1*0901 and are negatively associated with the disease. Since our analysis accounts for a large predominance of DRB1*1501 alleles in patients, its effect on the analysis of other HLA alleles could not be excluded. We used the total number of non-HLA DRB1*1501 alleles as denominator and still found a negative association of DRB1*0901 (OR = 0Á41, P = 0Á02) with the disease. These provide strong evidence supporting DRB1*0901 as a protective allele. However, DRB1*07 has a protective effect in Caucasian patients. 8 We suggest that it probably reflects a racial difference. In two studies involving 105 Caucasian patients with Goodpasture's disease, 33, 34 the DRB1*0701 allele frequency was 2Á4% (5/105 9 2), comparable with 5Á4% in the cases of the present study (v 2 = 2Á72, P = 0Á099). However, among healthy individuals, DRB1*0701 allele frequency was higher in Caucasian population than Chinese population (13Á3 versus 10Á3%, v 2 = 142Á02, P = 9Á63 9 10 À33 ), which we determined using the Allele Frequency Net Database and involved 1 362 965 healthy Caucasian and 8784 healthy Chinese individuals. DRB1*0901 is a rare allele reported in Caucasian populations with a frequency of 0Á9%; in contrast, it is commonly carried in Chinese individuals with 13Á0% frequency (v 2 = 14722Á08, P = 0). DRB1*0901 allele frequency was 0Á5% in 105 Caucasian patients with anti-GBM disease and 6Á4% in the cases of the present study (v 2 = 11Á41, P = 7Á32 9 10 À4 ). This racial difference may contribute to the finding that DRB1*0901 is a protective allele against the disease, which needs further validations from Chinese populations. In summary, DRB1*1501 and its encoding ARG13 and PRO11 in HLA-DRb1 chain are associated with the susceptibility to Goodpasture's disease. The presenting epitope is a3 134-148 with critical residues of isoleucine 137 , tryptophan 140 , glycine 142 , phenylalanine 143 and phenylalanine 145 . 
